# US 7,608,683 B2 · Stress proteins and peptides and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,608,683 B2
- Document ID: US7608683B2
- Status: Granted
- Kind: B2
- Application number: 11/080,458
- Filed: 2005-03-14
- Published: 2006-02-23
- Granted: 2009-10-27
- Earliest claimed: 2000-08-09
- Assignees: The Regents of the University of California
- Inventors: Salvatore Albani; Berent J. Prakken
- Web page: https://patentgrep.com/patent/US7608683B2

## CPC

- C07K 14/35: from Mycobacteriaceae (F)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/47: from mammals
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided are HLA pan DR-binding peptides and methods of using such peptides to modulate, block, or inhibit immune responses to effect treatment of immune-mediated diseases and conditions, such as inflammatory and autoimmune diseases, cancer, and microbial infections. These peptides and methods are also useful diagnostically to screen peptide or peptide analogs that can inhibit the pathogenic immune response or up-regulate an immune response against aberrant or invading cells, to monitor efficacy for therapeutic treatments, and to identify other agents that may be effective to inhibit or otherwise modulate an immune response such as by altering T cell functional phenotype, and even more particularly by modulating the regulatory phenotype of regulatory T cells and/or inducing emergence of T cells with a different functional phenotype.

## Claims

### Claim 1

An isolated peptide consisting of the amino acid sequence as set forth in SEQ ID NO: 24.

### Claim 2 (depends on 1)

The isolated peptide of claim 1, wherein the peptide is at least about 90% pure by weight.

### Claim 3 (depends on 1)

The isolated peptide of claim 1 wherein the peptide contains one or more D-amino acids.

### Claim 4 (depends on 1)

The isolated peptide of claim 1 wherein the peptide is covalently linked to an adjuvant.

### Claim 5 (depends on 4)

The isolated peptide of claim 4 wherein the adjuvant is selected from the group consisting of keyhole limpet hemocyanin, bovine serum albumin, human serum albumin, and isologous IgG.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising the peptide of claim 1 in a pharmaceutically acceptable carrier.

### Claim 7 (depends on 4)

A composition comprising a pharmaceutically acceptable carrier and the isolated peptide of claim 4.

### Claim 8 (depends on 7)

The composition of claim 7 wherein the peptide binds to a molecule selected from the group consisting of HLADR1, DR4, and DR7.

### Claim 9 (depends on 1)

The isolated peptide of claim 1, wherein the peptide is chemically synthesized.

### Claim 10 (depends on 1)

The isolated peptide of claim 1, wherein the peptide is glycosylated.